Stockreport

Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 [Yahoo! Finance]

Neumora Therapeutics, Inc.  (NMRA) 
PDF Outlook: Biotech Summit 2026 on February 11, Neumora executives shared additional data from the Phase 1b study of drug candidate NMRA-511. Neumora is developing NMRA-511 [Read more]